A leukotriene receptor antagonist.

Phase of research

Potential treatment - theoretical effect

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Montelukast is a leukotriene receptor antagonist used for prophylaxis and treatment of asthma, exercise-induced bronchoconstriction, and seasonal allergic rhinitis (DrugBank).

Montelukast on PubChem
Montelukast on Wikipedia

Marketed as



Structure image - Montelukast


Supporting references

Link Tested on Impact factor Notes Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection
Protein factor Small molecule Antibody In silico
in silico (machine learning) 13.49

Considered by the authors to be among the most relevant drugs identified in a machine-learning algorithm-based screening of compounds which considers causal protein-protein interactions, known drug targets, and specific signalling circuits in <a href=

Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19
3CLpro Small molecule In silico
in silico 2.80

Predicted to bind SARS-CoV-2 3C-like protease with A191V mutation.

Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19
Small molecule Case report
A patient

Systematic clinical improvement was observed in a patient following the treatment initiation using colchicine, montelukast, and acetylsalicylic acid. Sample size: 1. Dosage: 10 mg daily. 


AI-suggested references

Link Publication date
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: a multicenter, open-label, randomized controlled trial.
As a potential treatment of COVID-19: Montelukast
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2
Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol
Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.
Levocetirizine and montelukast in the COVID-19 treatment paradigm.
Colchicine, Aspirin, and Montelukast - A Case of Successful Combined Pharmacotherapy for Adult Multisystem Inflammatory Syndrome in COVID-19
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic.
Montelukast in hospitalized patients diagnosed with COVID-19
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients
3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?
Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing
The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.
Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials.

Clinical trials

ID Title Status Phase Start date Completion date
NCT04389411 The COvid-19 Symptom MOntelukast Trial Not yet recruiting Phase 3 Oct/01/2020 Dec/01/2021
  • Alternative id - 443807
  • Interventions - Drug: Montelukast 10mg
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 40 Years and older   (Adult, Older Adult)
  • Outcome measures - Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications
NCT05094596 Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19 Not yet recruiting Phase 4 Oct/22/2021 Jan/22/2022
  • Alternative id - ATATURK-BUGRA-001
  • Interventions - Drug: Standart treatment group|Drug: Montelukast sodium 10 mg treatment|Drug: Montelukast sodium 20 mg treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ataturk University, Erzurum, Turkey
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 180
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Pulmonary function test
NCT04714515 Montelukast - a Treatment Choice for COVID-19 Completed Feb/20/2020 Apr/20/2020
  • Alternative id - 01032020-7
  • Interventions - Drug: Montelukast|Drug: Hydroxychloroquine|Drug: Ivermectin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China|Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 150
  • Age - 20 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Patients admittance to ICU|Length of total stay at the hospital|Alleviating the symptoms of COVID-19|Interleukin levels
NCT04718285 Investigation the Effect of Montelukast in COVID-19 Not yet recruiting Phase 2 Jan/30/2021 May/30/2021
  • Alternative id - MON786.168.1
  • Interventions - Drug: Montelukast Oral Tablet|Drug: Montelukast plus Favicovir (Favipiravir)|Drug: Favicovir (Standard Treatment)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bahcesehir University, School of Medicine, Department of Biophysics,, Istanbul, Turkey
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 380
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalized patient rates|Emergency room visit rates of patients|Time to emergency room visit|Time to hospitalization|Inpatient length of stay|Time to ICU admission|Time to intubation|Mortality rate|Family members rates with PCR positive test results|Number/characteristics of AEs and SAEs|Changes in blood pressure from baseline|Changes in pulse from baseline|Changes in respiratory rate from baseline|Changes in fever from baseline|Changes in oxygen saturation from baseline
NCT04695704 Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: Not yet recruiting Phase 3 Apr/01/2021 Dec/31/2022
  • Alternative id - 4R21/006
  • Interventions - Drug: Montelukast|Other: placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 284
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - COP Assessment Test Scale (CAT)|1min sit-to-stand test|O2 desaturation|Visual Analogical Scale (VAS)|All-cause mortality|Number of visits to primary care|Number of visits to the emergency room|Number of hospital admissions.|Medication side effects|Days of sick leave|Factors of inflamatory and prothrombotic processes: D-Dimer, N-terminal prohormone of brain natriuretic peptide (NT Pro-BNP), C-reactive protenin and Antinuclear antibodies (ANA)